Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground
The company said the NEAT trial in ataxia telangiectasia did not meet the primary and key secondary endpoints.
Scrip - January 30, 2026

Amgen Returns Eczema Drug To Kyowa Kirin On Marketability Doubts
Rocatinlimab has met primary endpoints in Phase III studies, but analysts question the Kyowa-discovered drug’s market potential due to tolerability and unspectacular efficacy.
Scrip - January 30, 2026

India OTC Market: $10.7bn Opportunity Awaits Pharma, But Will Regulatory Reform Flow?
Huge opportunities for OTC therapies loom in India, as consumerization brings structural reset in healthcare. Success stories on Rx-to-OTC transition augur well for pharma, but a predictable regulatory roadmap will be pivotal for sustainable growth.
HBW Insight - January 30, 2026

Roche Awaits Key Readouts In 2026 – Including Its Potential Biggest Ever Drug
Roche has a handful of key Phase III readouts from potential blockbusters this year, with its oral SERD, giredestrant, expected to be the centerpiece of a future breast cancer franchise.
Scrip - January 30, 2026

Nestlé Taps Into AI To Offer Personalized Supplement Advice
The Solgar Smart Mirror harnesses AI to deliver personalized wellness insights, according to Nestlé Health Science.
HBW Insight - January 30, 2026

$10.7bn India OTC Opportunity Awaits Pharma, Will Regulatory Reform Flow?
Huge opportunities for OTC therapies loom in India, as consumerization brings structural reset in healthcare, as per a new report by EY-Parthenon. Success stories on Rx-to-OTC transition augur well for pharma, but a predictable regulatory roadmap will be pivotal for sustainable growth.
Scrip - January 30, 2026

Sanofi’s Hudson Cuts Through Noise To Champion Vaccines
The French firm will always ‘defend with evidence’ the positive impact of vaccination, ‘irrespective of who is in office,’ the French firm’s CEO has declared.
Scrip - January 30, 2026

Executives On The Move: Three CEOs And Four CFOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Odyssey Therapeutics and Taiho Oncology, plus Ocular Therapeutix gets a new global chief commercial officer from Merck.
Scrip - January 30, 2026

‘Junk’ And ‘Bogus’: Novo Hit With US Victoza ‘Pay-For-Delay’ Suit
A US class action suit alleges that a settlement between Teva and Novo Nordisk illegally delayed generic Victoza for 16 months, kept prices high and transferred an estimated $903m in value to Teva.
Generics Bulletin - January 30, 2026

‘It’s A Great Opportunity But It’s Also Late’ – Samsung Bioepis’ Woollett On Biosimilar Streamlining
Regulatory streamlining represents a paradigm shift for the biosimilars industry, but does it go far enough? Gillian Woollett, Samsung Bioepis’ head of regulatory strategy and policy, says streamlining must be accompanied by a sustainable economic environment for biosimilars to ensure global access.
Generics Bulletin - January 30, 2026

The EU Needs A System That Learns Progressively Instead Of Swinging The Pendulum
If medtech regulation is to work for patients, industry and society, Europe must move from political positioning to evidence-driven policymaking. It is time to avoid repeating the self-destructive cycle.
Medtech Insight - January 30, 2026

Positive Long-Term China Safety Data For Ascletis’s Oral Acne Contender
Following the recent acceptance of a China NDA for first-in-class drug denifanstat for acne in China, Ascletis has announced positive topline results from an open-label Phase III trial focusing on the product’s long-term safety.
Scrip - January 30, 2026

AstraZeneca Bets $18.5bn On CSPC’s Sustained-Release And AI Peptide Platforms In Weight Management
UK major will bag CSPC’s eight preclinical drug candidates in weight management, including most advanced asset SYH2082, a long-acting GLP-1/GIP receptor agonist with once-monthly dosing potential.
Scrip - January 30, 2026

Revlon ColorSilk Claims Focus Of Henkel-Prompted NAD Assessment
New York-based Revlon was able to demonstrate substantiation for two claims for its namesake ColorSilk with bond Repair Complex hair color, while committing to modifying or discontinuing several other claims that the National Advertising Division concluded were not supported.
HBW Insight - January 30, 2026

Kenvue Shareholder Meeting Shows Strong Support To Accept Kimberly-Clark’s Nearly $50Bn Offer
Both companies announced that during special meetings on Jan. 29, their shareholders voted nearly unanimous support for Kimberly-Clark’s $48.7bn acquisition proposed in November at $3.50 per share plus 0.14625 share for each Kenvue share.
HBW Insight - January 30, 2026